๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leeds
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leeds, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
545
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 670 Birmingham 470 Glasgow 437 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Janssen Research & Development, LLC14 AbbVie9 Bristol-Myers Squibb9 Novartis Pharmaceuticals9
Site city
London2010 Manchester670 Birmingham470 Glasgow437 Cambridge418
All 425 cities
Target enrolment
to

Trials with a site in Leeds

317 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
GlaxoSmithKline
Phase 3
514
Leeds, London
2024-12-12
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Hull, Leeds, London, Northwood
2024-12-12
Recruiting
DERMATOMICS: Identifying Regulators of Skin Homeostasis
NCT06894654Systemic Sclerosis (SSc)
Relation Therapeutics
Observational
500
Leeds, London
2024-12-10
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon
2024-12-04
Active, closed
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.
Phase 3
81
London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth
2024-12-01
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Active, closed
RCT on the Performance and Safety of LightForceยฎ Therapy Lasers on Knee Osteoarthritis Pain Reduction (SPARK)
NCT06654739Osteoarthritis of Knee
DJO UK Ltd
Not applicable
64
Leeds
2024-11-23
Active, closed
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
50
Cardiff, Leeds, Liverpool, London, Southampton
2024-11-21
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
2024-11-21
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155Systemic Sclerosis (SSc)
argenx
Phase 2
81
Leeds, London, Luton
2024-11-11
Active, closed
A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
NCT06713135Duchenne Muscular Dystrophy
Santhera Pharmaceuticals
Phase 4
80
Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle
2024-11-10
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Recruiting
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFฮฑ Inadequate Response
NCT06641089Arthritis, Psoriatic
MoonLake Immunotherapeutics AG
Phase 3
600
Westcliff-on-Sea, Barnet, Leeds, Wolverhampton
2024-10-15
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
Incyte Corporation
Phase 2
130
Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2024-10-11
Active, closed
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789TGCT
SynOx Therapeutics Limited
Phase 3
128
Leeds, London
2024-10-09
Active, closed
Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient's Emotional Wellbeing, and Perceptions of Total Knee Replacement Surgery for the Treatment of Knee Arthritis
NCT06585267Complete Questionnaires Following TKR Surgery
Invibio Ltd
Observational
167
Leeds
2024-10-07
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Brighton, Glasgow, Leeds, London, Southampton
2024-09-18
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
Epsilogen Ltd
Phase 1
45
Bristol, Edinburgh, Leeds, London, Southampton
2024-09-03
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Birmingham, Cambridge, Leeds, Leicester, London, Northwood
2024-08-28
Recruiting
Observational Study of Venus P-Valve
NCT05835349Right Ventricular Outflow Tract Dysfunction
Venus MedTech (HangZhou) Inc.
Observational
200
Leeds, London
2024-08-26
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
Cottingham, Edinburgh, Leeds, London
2024-08-26
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
Kite, A Gilead Company
Phase 3
452
Bristol, Cardiff, Leeds, London, Newcastle
2024-08-23
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Birmingham, Dundee, Glasgow, Greater London, Leeds, London
2024-08-12
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
686
London, Sutton, Glasgow, Leeds, Manchester
2024-07-24
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
Celldex Therapeutics
Phase 3
976
Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley
2024-07-19
Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306Anemia, Sickle Cell, Healthy Volunteers
Bristol-Myers Squibb
Phase 1/2
224
East Sussex, London, Leeds
2024-07-17
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Cambridge, Leeds, London, Newcastle upon Tyne
2024-06-29
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Truro, London, Edinburgh, Leeds
2024-06-24
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.
Phase 3
762
Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth
2024-05-24
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester
2024-05-19
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,666
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
argenx
Phase 3
119
Glasgow, Leeds
2024-04-16
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjรถgren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjรถgren's Syndrome (SS)
Amgen
Phase 3
434
Leeds, London
2024-04-08
Recruiting
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
NCT06265727Solid Tumor, Adult
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton
2024-04-01
Recruiting
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Splice Bio
Observational
75
London, Leeds, Manchester, Oxford
2024-03-29
Recruiting
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases
AliveCor
Not applicable
1,000
Leeds, Edinburgh
2024-03-12
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
Sanofi
Phase 3
464
Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool
2024-02-29
Active, closed
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
NCT06298955Paroxysmal Nocturnal Hemoglobinuria
Omeros Corporation
Phase 2
25
Leeds
2024-02-19
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
Genmab
Phase 3
1,095
Plymouth, London, Portsmouth, Leeds, Manchester, Newcastle upon Tyne
2024-02-05
Active, closed
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
NCT06237335Cystic Fibrosis
ReCode Therapeutics
Phase 2
128
Birmingham, Cambridge, Leeds, London, Nottingham, Southampton
2024-02-01
Recruiting
OSsIRIS Study - A Post-market Clinical Follow-up Investigation.
NCT06156904Surgically Created Bone Defects or Bone Defects/Voids Resulting From Traumatic Injury
GreenBone Ortho S.p.A.
Observational
135
Hull, Leeds
2024-01-31
Active, closed
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Cardiomyopathy, Hypertrophic
Bristol-Myers Squibb
Phase 4
63
Leeds
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
Sanofi
Phase 3
260
Cardiff, London, Leeds, Manchester, Newcastle upon Tyne
2024-01-23
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
Glasgow, Leeds, London, Oxford
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
Deciphera Pharmaceuticals, LLC
Phase 3
54
London, Leeds
2023-12-13
Active, closed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals
Phase 2
145
Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham
2023-12-11
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca
Phase 1/2
564
Cambridge, Leeds, London, Manchester
2023-12-05
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
NCT06166056Bronchiectasis
Chiesi Farmaceutici S.p.A.
Phase 1/2
45
Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton
2023-11-29
Recruiting
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
NCT05935358Severe Hemophilia A
Octapharma
Phase 4
28
Leeds
2023-11-28
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Cannock, Leeds, London, Sheffield
2023-11-08
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2023-10-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
1,600
Leeds, London, Manchester
2023-10-26
Recruiting
ZNN Bactiguard Retrograde Femoral Nails PMCF Study
NCT05276674Femoral Fracture
Zimmer Biomet
Observational
100
Leeds, Manchester, Stockport
2023-10-23
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenstrรถm Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
BeOne Medicines
Phase 2
114
Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth
2023-10-23
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
Manchester, Leeds, Cardiff, Glasgow, London
2023-10-20
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Aberdeen, Burton-on-Trent, Cambridge, Derby, Guildford, Ipswich, Lancaster, Leeds
2023-10-05
Active, closed
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
NCT06007677Hereditary Angioedema
Astria Therapeutics, Inc.
Phase 2
56
Cambridge, Leeds
2023-09-26
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
GlaxoSmithKline
Phase 2/3
300
Wakefield, Birmingham, Leeds, London, Portsmouth
2023-09-13
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell
2023-08-28
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Ilford, Swinton, Aberdeen, Chertsey, Leeds, Motherwell, Preston, Sheffield, SouthYorkshire
2023-07-11
Active, closed
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227Obesity
Novo Nordisk A/S
Phase 3
210
Birmingham, Bristol, Leeds, Liverpool, Southampton
2023-07-07
Active, closed
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480SLE
Alumis Inc
Phase 2
408
Leeds, London, Southampton
2023-06-26
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Active, closed
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
290
Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York
2023-06-13
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
288
Leeds, Doncaster
2023-04-21
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
Scholar Rock, Inc.
Phase 3
238
Leeds, London, Oxford
2023-04-17
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Leeds, London, Manchester
2023-04-04
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Gilead Sciences
Phase 2
192
Birmingham, Leeds, London
2023-03-16
Recruiting
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
NCT05744921Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals
Phase 3
202
Leeds
2023-03-07
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
NCT05496998Mitral Regurgitation
Medtronic Cardiovascular
Not applicable
400
Brighton, Leeds, London
2023-02-07
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 3
606
Plymouth, Cringleford, Glasgow, Birmingham, Leeds, Taunton
2023-01-10
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Birmingham, Leeds, London
2022-12-30
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Dartford, Huddersfield, Leeds, London, Plymouth, Preston, Sutton
2022-12-29
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Leeds, Leicester, Surrey, Wolverhampton
2022-12-15
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Active, closed
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
NCT06211634Glanzmann Thrombasthenia
Hemab ApS
Phase 1/2
57
Birmingham, Leeds, London, Whitechapel
2022-12-13
Rows per page Showing 101–200 of 317
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds?page=2

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 24 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 317 of those studies with a site in Leeds.

How many clinical trials are recruiting in Leeds?

151 of the 317 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:15 UTC sync. A further 7 have not yet opened recruitment, 157 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.